FierceBiotech

Why Model Medicines needs to ‘discover new colors’ in its AI drug discovery quest fiercebiotech.com/biotech/how-mo…

Despite prolonged policy uncertainty in the U.S., many healthcare and life sciences execs are still seeing opportunities amid the tumult. On “The Top Line,” Fierce Pharma's Fraiser Kansteiner talks with @PwC's U.S. health industries leader about tariffs, drug pricing reform, AI and the future of U.S. healthcare innovation. fiercepharma.com/pharma/health-…

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza fiercebiotech.com/biotech/alumis…

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome program after the FDA put a full clinical hold on its trials. fiercebiotech.com/biotech/aardva…

Biogen advances Alzheimer’s tau program despite midphase miss fiercebiotech.com/biotech/biogen…

After axing its lead obesity asset last year, BioAge Labs has turned its attention to attacking inflammation in its pursuit of treatments for aging-related illnesses. fiercebiotech.com/biotech/ceo-bi…

Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program fiercebiotech.com/biotech/fosun-…

With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’ fiercebiotech.com/biotech/1b-nov…

Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled fiercebiotech.com/biotech/enterp…

Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. The deal could be worth up to $15.2 billion. fiercebiotech.com/biotech/bms-in…

A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public. fiercebiotech.com/biotech/quantu… $AMGN

Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data fiercebiotech.com/biotech/ox40-d…

Daiichi Sankyo targets global top 5 oncology rank by 2035 fiercepharma.com/pharma/daiichi…

BeOne Medicines has shaken up its early pipeline, dropping five phase 1 cancer programs and stopping a phase 2 arthritis trial based on new data. fiercebiotech.com/biotech/beone-…

🎧On this week’s episode of “The Top Line,” @FiercePharma’s Fraiser Kansteiner sits down with @KPMG's Chris Young to break down what the latest Trump tariff threats could mean for drugmakers, especially smaller biopharmas navigating an increasingly uncertain trade landscape. fiercepharma.com/pharma/revisit…

Analysts cut enGene cancer sales forecast after updated data widen gap to J&J fiercebiotech.com/biotech/analys…

Here's this week's Chutes & Ladders, our roundup of major leadership hires, exits and retirements across the biopharma industry. fiercebiotech.com/biotech/chutes…

Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million IPO this morning. fiercebiotech.com/biotech/odysse… $ODTX

Banyan BioInnovations is debuting with more than $100 million aimed at developing independent companies for promising clinical-stage treatments, plus a partnership with global CRO Icon. fiercebiotech.com/cro/banyan-bio…

Antibodies that stop measles from stabbing cells could become new treatments for the surging virus, study suggests fiercebiotech.com/research/antib…